• PDF / 170,111 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 42 Downloads / 163 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 6 case reports In a single-centre and retrospective study of 46 patients, conducted between January 2010 and September 2018, six adult patients [exact ages not stated; not all sexes stated] were described, they developed toxidermia, gastrointestinal toxicity or acquired resistance during treatment with clindamycin or combination of clindamycin and rifampicin for bone and joint infections caused by erythromycin-resistant Staphylococcus spp. Additionally, one patient exhibited failure with clindamycin to control the bone and joint infection [not all dosages, routes and outcomes stated; not all time to reaction onsets stated]. All the patients, who had a history of bone and joint infections caused by erythromycin-resistant Staphylococcus spp, received oral clindamycin 600mg and rifampicin 600mg twice/day. Out of the 6 patients, one male, who had a history of hip prosthesis infection and 2-stage exchange revision, started receiving clindamycin and rifampicin combination and developed toxidermia at day 7. He exhibited failure to control the bone and joint infection. He was treated with oxacillin and fusidic acid. However, after 1 month, he died due to spacer infection. Three patients, who received clindamycin and rifampicin combination developed toxidermia at day 7 (one patient), day 21 (one patient) and day 26 (one patient). The clindamycin treatment was discontinued in these patients. Out of the remaining two patients, one patient, who received clindamycin and fusidic acid, developed gastrointestinal toxicity at day 16 and the clindamycin treatment was discontinued. Another patient, who had a history of chronic osteomyelitis due to S. aureus and underwent repeated surgical interventions, received clindamycin and fusidic acid combination. However, the patient had a relapse and developed acquired resistance to clindamycin. Bonnaire A, et al. Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp. Diagnostic Microbiology and Infectious Disease 99: 115225, No. 1, Jan 2021. Available from: URL: http://doi.org/10.1016/j.diagmicrobio.2020.115225 803520625

0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Dec 2020 No. 1834